Test your knowledge in this week's edition of the MM&M Weekly News Quiz
Longer-term use of AstraZeneca's Brilinta approved; Google streamlines health-related searches; Zarxio's price is higher than expected
The conference will offer a glimpse at new data testing possible treatment strategies for combination therapies in the first-line setting.
Sandoz plans to take a branded approach as it launches the first FDA-approved biosimilar product.
Novartis launches Zarxio, the first US biosimilar; UCB sells its generic business; one-third of children with ADHD are diagnosed before they turn six
Advertising and marketing agencies turn their attention to the pharma market in the Asia-Pacific region.
The motion denied Amgen's bid for a temporary injunction that would have prevented the launch of Zarxio, the first FDA-approved biosimilar and a competitor to Amgen's Neupogen.
Novartis and Amgen form neuroscience collaboration; the FDA approves a drug for people undergoing chemotherapy; a judge considers denying Pfizer's request to toss federal lawsuit
The longtime creative director was instrumental in building the powerhouse agency that is now called FCB Health.
The search giant and the drugmaker will develop new tools to monitor the disease and improve patient outcomes.
- The MM&M Weekly News Quiz: September 4
- Five things for pharma marketers to know: Friday, September 4
- New data expected at lung-cancer conference on experimental drug combos
- Sandoz: Zarxio marketing to be similar to a branded-drug launch
- Five things for pharma marketers to know: Thursday, September 3, 2015
Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.